Bionano Genomics, Inc. · NASDAQ:BNGO
Bionano Genomics — Q3 2021 Earnings Presentation
16 slides from Bionano Genomics's earnings presentation, Nov 4, 2021
Slide 1: Q3 Webcast and Call November 4, 2021
Q3 Webcast and Call November 4, 2021
Slide 2: Legal Disclaimer
2 Legal Disclaimer This presentation contains forward-looking statements. Forward-looking statements describe future expectations, plans, results or strategies and are generally preceded by terms such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estim
Slide 3: Creating the Leading Variant Analysis Platform in Genomics
+ Creating the Leading Variant Analysis Platform in Genomics
Slide 4: Acquisition Expected to Accelerate and Broaden Bionano's Market Leadership
4 Acquisition Expected to Accelerate and Broaden Bionano’s Market Leadership in Cytogenomics and Comprehensive Genome Analysis • Our vision is to make OGM ubiquitous, this vision requires exceptional software • Delivering seamless integration with as many data types as possible, OGM can be used more
Slide 5: Integration Plan & Operational Structure
5 Integration Plan & Operational Structure • Dr. Soheil Shams becomes Chief Informatics Officer (CIO) of Bionano • Location in El Segundo, CA, preserved as Bionano software hub • CIO integrated into Bionano software/informatics programs – Drive integration of SV analysis pipelines into NxClinical so
Slide 6: Summary of Q3 Results
6 Summary of Q3 Results R. Erik Holmlin CEO eholmlin@bionanogenomics.com
Slide 7: Q3 2021: Creating Momentum Heading into YE
7 Q3 2021: Creating Momentum Heading into YE Q2 New Applications in Prenatal Testing, Cancer Research & Development Presented 24 10 New Publications in Q3 Talks and Posters Saphyr Systems Shipped 141 total installed Advancing Go to Market – Bionano Data Centric Services, Reagent Rentals & Capital Pu
Slide 8: Clinically Focused Publications in Q3, 2021
8 Clinically Focused Publications in Q3, 2021 Clinical area of focus Authors Institution Database/Journal Key findings OGM as a tool in clinical cytogenetics/genomics Khan, W.A. and Toledo, D.M. Dartmouth Adv. in Mol. Path. Review OGM in the clinic Solid tumor: Medulloblastoma Chapman, O., et al UCS
Slide 9: Clinical Affairs Summary
9 Clinical Affairs Summary
Slide 10: Four Large Clinical Studies Getting Underway to Support Penetration of our Target Markets
10 Four Large Clinical Studies Getting Underway to Support Penetration of our Target Markets & Support Potential Third-Party Reimbursement Constitutional - Prenatal - Constitutional - Pediatric - Oncology - Heme Malignancies - Oncology - Solid Tumor - Amnio & CVS Illustrate HOW Saphyr can help with
Slide 11: Financial Overview
11 Financial Overview Chris Stewart CFO cstewart@bionanogenomics.com
Slide 12: Q3 2021 – Financial Results and Key Highlights
12 Q3 2021 – Financial Results and Key Highlights • Total revenue was $4.7M, up 112% from Q3 2020 • Year-on-year revenue was up in all geographies and across both product and service revenue • Post quarter-end, BioDiscovery acquisition is expected to be moderately accretive Strong cash and short-ter
Slide 13: Summary
13 Summary R. Erik Holmlin CEO eholmlin@bionanogenomics.com
Slide 14: Key Anticipated Milestones Expected to Drive Value for BNGO
14 Commercial release of prenatal assays for Saphyr and expansion of Saphyr’s menu of pediatric assays Key Anticipated Milestones Expected to Drive Value for BNGO 3Q Accreditation of Saphyr based LDTs for ALL & FSHD in certain EU markets 2Q 4Q • Interim publication of results from pediatric clin
Slide 15: Questions & Answers
Questions & Answers Contact: R. Erik Holmlin CEO eholmlin@bionanogenomics.com Chris Stewart CFO cstewart@bionanogenomics.com
Slide 16: Bionano Genomics: 3 Key Areas of Focus
16 To continuously innovate to bring new capabilities that accelerate throughput Bionano Genomics: 3 Key Areas of Focus In clinical research and discovery research markets where OGM complements any type of sequencing Through Bionano pivotal clinical studies and third- party support and advocacy Buil